Aravive Announces First Patient Dosed in Phase 1b/2 Clinical Trial of AVB-500 in Patients with Clear Cell Renal Cell Carcino...
March 08 2021 - 7:00AM
Aravive, Inc. (Nasdaq: ARAV), a clinical-stage oncology
company developing transformative therapeutics, today
announced that the Company has dosed its first patient in an open
label Phase 1b/2 clinical trial to evaluate the safety,
pharmacokinetic, and preliminary clinical activity of AVB-500,
including progression free survival. The trial will enroll patients
with advanced clear cell renal cell carcinoma (ccRCC) that have
progressed on front-line treatment.
AVB-500 is an ultra-high affinity decoy protein that targets the
GAS6-AXL signaling pathway associated with tumor cell growth and is
currently being evaluated in clinical trials for the treatment of
ovarian, kidney and urothelial cancer.
“The preclinical data of AVB-500 in ccRCC suggest a great
potential in treating this cancer without adding toxicity,” said
Gail McIntyre, Ph.D., Chief Executive Officer of Aravive. “Given
that there is a large unmet need for effective treatments in renal
cell carcinoma, we look forward to advancing the development of
AVB-500 to potentially improve outcomes for patients with renal
cancer.”
Kidney cancer is a leading cause of cancer-related deaths in the
United States and is among the 10 most common cancers in both men
and women. ccRCC is a cancer of the kidney and accounts for more
than 75% of malignant kidney tumors. Metastasis to distant organs
including the lung, bone, liver and brain is the primary cause of
death in kidney cancer patients, and only 12% of people with
metastatic kidney cancer will survive past 5 years. According to
the American Cancer Society, it is estimated that there will be
approximately 76,080 new cases of kidney cancer and 13,780 people
will die from this disease in the United States during 2021.
“AXL/GAS6 is associated with poor prognosis and resistance
mechanisms in renal cell carcinoma. This trial will focus on safety
and early efficacy signals of AVB-500 in combination with
cabozantinib in patients who have progressed after front-line
treatment of kidney cancer. This trial presents a unique
opportunity to study a new therapeutic target in combination with
cabozantinib,” said Kathryn Beckermann, M.D., Ph.D., Assistant
Professor, Division of Hematology and Oncology, Vanderbilt
University Medical Center and lead investigator for the trial.
The Phase 1b portion of the trial will evaluate AVB-500 in
combination with cabozantinib, a small molecule inhibitor of the
tyrosine kinases c-Met and VEGFR2. The trial will enroll up to 18
patients in three dosing arms (15 mg/kg, 20 mg/kg and 25 mg/kg) to
evaluate tolerability, pharmacokinetics, pharmacodynamics, and
clinical activity. The controlled, randomized, open-label Phase 2
portion of the trial will enroll up to 45 patients and investigate
the recommended AVB-500 dose identified during the Phase 1b portion
of the trial in combination with cabozantinib versus cabozantinib
alone. The primary endpoint of the Phase 2 portion of the trial is
progression-free survival and the secondary endpoints are objective
response rate, duration of response, clinical benefit rate and
overall survival. The Phase 1b/2 trial is listed on
clinicaltrials.gov NCT04300140.
About AVB-500AVB-500 is a therapeutic
recombinant fusion protein that has been shown to neutralize GAS6
activity by binding to GAS6 with very high affinity in preclinical
models. In doing so, AVB-500 selectively inhibits the GAS6-AXL
signaling pathway, which is upregulated in multiple cancer types
including ovarian cancer and clear cell renal cancer. In
preclinical studies, GAS6-AXL inhibition has shown anti-tumor
activity in combination with a variety of anticancer therapies,
including radiation therapy, immuno-oncology agents, and
chemotherapeutic drugs that affect DNA replication and repair.
Increased expression of AXL and GAS6 in tumors has been correlated
with poor prognosis and decreased survival and has been implicated
in therapeutic resistance to conventional chemotherapeutics and
targeted therapies. AVB-500 is currently being evaluated in
clinical trials and has been granted Fast Track Designation by the
U.S. Food and Drug Administration in platinum resistant recurrent
ovarian cancer. Analysis of all safety data to date showed that
AVB-500 has been generally well-tolerated with no dose-limiting
toxicities or unexpected safety signals.
About AraviveAravive, Inc. is a
clinical-stage oncology company developing transformative
therapeutics designed to halt the progression of life-threatening
diseases. Aravive is based in Houston, Texas and received a Product
Development Award from the Cancer Prevention & Research
Institute of Texas (CPRIT) in 2016. Aravive’s lead product
candidate, AVB-500, is an ultra-high affinity decoy protein that
targets the GAS6-AXL signaling pathway associated with tumor cell
growth. Aravive successfully completed a Phase 1b trial of AVB-500
in platinum resistant ovarian cancer and is in the process of
initiating a registrational Phase 3 trial of AVB-500 at a dose of
15 mg/kg. While the Phase 1b trial of AVB-500 in platinum resistant
ovarian cancer was a safety trial and not powered to demonstrate
efficacy, all 5 patients in the 15 mg/kg cohort experienced
clinical benefit, with 1 complete response, 2 partial responses,
and 2 stable disease. For more information, please
visit www.aravive.com.
Forward-Looking StatementsThis communication
contains forward-looking statements (including within the meaning
of Section 21E of the United States Securities Exchange Act of
1934, as amended, and Section 27A of the United States Securities
Act of 1933, as amended), express or implied, such statements
regarding the potential for AVB-500 to treat clear cell renal cell
carcinoma without adding toxicity and advancing the development of
AVB-500 to potentially improve outcomes for patients with renal
cancer. Forward-looking statements are based on current beliefs and
assumptions, are not guarantees of future performance and are
subject to risks and uncertainties that could cause actual results
to differ materially from those contained in any forward-looking
statement as a result of various factors, including, but not
limited to, risks and uncertainties related to: our ability to show
the potential for AVB-500 to treat clear cell renal cell carcinoma
without adding toxicity, our ability to advance the development of
AVB-500 to potentially improve outcomes for patients with renal
cancer, the Company's dependence upon AVB-500, AVB-500's ability to
have favorable results in clinical trials and ISTs, the clinical
trials of AVB-500 having results that are as favorable as those of
preclinical and clinical trials, the ability to receive regulatory
approval, potential delays in the Company's clinical trials due to
regulatory requirements or difficulty identifying qualified
investigators or enrolling patients especially in light of the
COVID-19 pandemic, the risk that AVB-500 may cause serious side
effects or have properties that delay or prevent regulatory
approval or limit its commercial potential; the risk that the
Company may encounter difficulties in manufacturing AVB-500, if
AVB-500 is approved, risks associated with its market acceptance,
including pricing and reimbursement, potential difficulties
enforcing the Company's intellectual property rights, the Company's
ability to expand development into additional oncology indications,
and the Company's reliance on its licensor of intellectual property
and financing needs. The foregoing review of important factors that
could cause actual events to differ from expectations should not be
construed as exhaustive and should be read in conjunction with
statements that are included herein and elsewhere, including the
risk factors included in the Company's Annual Report on Form 10-K
for the fiscal year ended December 31, 2019, recent Current Reports
on Form 8-K and subsequent filings with the SEC. Except as required
by applicable law, the Company undertakes no obligation to revise
or update any forward-looking statement, or to make any other
forward-looking statements, whether as a result of new information,
future events or otherwise.
Contacts:Media:Sheryl Seapy,
W2Osseapy@w2ogroup.com(213) 262-9390
Investors:Luke Heagle, W2O lheagle@w2ogroup.com (910)
726-1372
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aravive (NASDAQ:ARAV)
Historical Stock Chart
From Apr 2023 to Apr 2024